New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
13:55 EDTARIAARIAD announces 12-month data from PACE trial of ponatinib
ARIAD Pharmaceuticals announced twelve-month follow-up data from the pivotal PACE trial of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with resistant or refractory chronic myeloid leukemia, CML, or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that 56 percent of chronic-phase CML patients in the trial, including 70 percent of patients with a T315I mutation, achieved a major cytogenetic response (MCyR), the primary end-point for chronic-phase CML patients. The data are being featured today at 4:30 p.m., ET, in an oral presentation at the 54th Annual Meeting of the American Society of Hematology, ASH, being held in Atlanta, Georgia. ARIAD filed for regulatory approval of ponatinib in the third quarter of 2012 in the U.S. and in the E.U. based on clinical data from the pivotal PACE trial.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
07:37 EDTARIAARIAD announces data presentations at EHA Congress
Subscribe for More Information
May 20, 2015
10:29 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
May 19, 2015
11:59 EDTARIAOptions with decreasing implied volatilit
Subscribe for More Information
May 18, 2015
10:37 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 14, 2015
08:04 EDTARIAARIAD to present data on Iclusig, brigatinib at ASCO meeting
Subscribe for More Information
May 12, 2015
07:52 EDTARIALeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use